Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from ...

Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dystrophy care, targeting broader ages and mutations. We are witnessing the fastest pivot in rare-disease ...

Pilot with European Banking Authority tests vLEI technology for secure digital identity management in regulatory reporting scenarios The pilot results clearly shows vLEI’s capacity to enhance digital ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Regenxbio (RGNX) stock in focus as the company shares promising trial data for its RGX-202 gene therapy for Duchenne muscular ...

hus.fi Methods: All 48 exons of the CACNA1F gene were screened for mutations by DNA sequencing ... CORDX, X linked cone-rod dystrophy CSNBX, congenital stationary night blindness ERG, ...

Pepgen will stop development of its Duchenne MD exon-skipping therapy PGN-ED051 after increases in dystrophin levels proved ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Identification of disease based on mutations in the gene sequences is an essential and challenging task in the medical diagnosis of genetic disorders such as Muscular dystrophy. Muscular dystrophy is ...

Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.